The MBD7 complex promotes expression of methylated transgenes without significantly altering their methylation status
Abstract
DNA methylation is associated with gene silencing in eukaryotic organisms. Although pathways controlling the establishment, maintenance and removal of DNA methylation are known, relatively little is understood about how DNA methylation influences gene expression. Here we identified a METHYL-CpG-BINDING DOMAIN 7 (MBD7) complex in Arabidopsis thaliana that suppresses the transcriptional silencing of two LUCIFERASE (LUC) reporters via a mechanism that is largely downstream of DNA methylation. Although mutations in components of the MBD7 complex resulted in modest increases in DNA methylation concomitant with decreased LUC expression, we found that these hyper-methylation and gene expression phenotypes can be genetically uncoupled. This finding, along with genome-wide profiling experiments showing minimal changes in DNA methylation upon disruption of the MBD7 complex, places the MBD7 complex amongst a small number of factors acting downstream of DNA methylation. This complex, however, is unique as it functions to suppress, rather than enforce, DNA methylation-mediated gene silencing.
Data availability
-
LIL, an α-crystallin/Heat Shock Protein 20 family protein, associates with the Methyl -CpG-Binding Domain protein MBD7 to suppress cytosine methylation and transcriptional gene silencing in Arabidopsis (mRNA-seq)Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE83557).
-
LIL, an α-crystallin/Heat Shock Protein 20 family protein, associates with the Methyl -CpG-Binding Domain protein MBD7 to suppress cytosine methylation and transcriptional gene silencing in Arabidopsis (smallRNA-seq)Publicly available at the NCBI Gene Expression Omnibus (accession no: GSE59639).
-
LIL, an α-crystallin/Heat Shock Protein 20 family protein, associates with the Methyl -CpG-Binding Domain protein MBD7 to suppress cytosine methylation and transcriptional gene silencing in ArabidopsisPublicly available at the NCBI Gene Expression Omnibus (accession no: GSE83355).
Article and author information
Author details
Funding
Gordon and Betty Moore Foundation (GBMF3046)
- Xuemei Chen
National Science Foundation of China (91440105)
- Xuemei Chen
National Science Foundation of China (30970265)
- Beixin Mo
National Science Foundation of China (31210103901)
- Beixin Mo
Guangdong Innovation Research Team Fund (2014ZT05S078)
- Xuemei Chen
National Institutes of Health (GM061146)
- Xuemei Chen
National Academy of Agricultural Science (PJ008725)
- So Youn Won
China Scholarship Council
- Dongming Li
Glenn Center for Aging Research at the Salk Institute
- Ana Marie S Palanca
Helmsley Charitable Trust
- Ana Marie S Palanca
- Julie A Law
National Institutes of Health (GM112966)
- Julie A Law
National Institutes of Health (GM089778)
- James A Wohlschlegel
National Institutes of Health (P30 014195)
- Ana Marie S Palanca
- Julie A Law
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- Steven Henikoff, Howard Hughes Medical Institute, Fred Hutchinson Cancer Research Center, United States
Version history
- Received: July 25, 2016
- Accepted: April 24, 2017
- Accepted Manuscript published: April 28, 2017 (version 1)
- Version of Record published: June 7, 2017 (version 2)
Copyright
© 2017, Li et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 2,817
- views
-
- 751
- downloads
-
- 18
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Further reading
-
- Chromosomes and Gene Expression
Eukaryotic chromatin is organized into functional domains, that are characterized by distinct proteomic compositions and specific nuclear positions. In contrast to cellular organelles surrounded by lipid membranes, the composition of distinct chromatin domains is rather ill described and highly dynamic. To gain molecular insight into these domains and explore their composition, we developed an antibody-based proximity-biotinylation method targeting the RNA and proteins constituents. The method that we termed Antibody-Mediated-Proximity-Labelling-coupled to Mass Spectrometry (AMPL-MS) does not require the expression of fusion proteins and therefore constitutes a versatile and very sensitive method to characterize the composition of chromatin domains based on specific signature proteins or histone modifications. To demonstrate the utility of our approach we used AMPL-MS to characterize the molecular features of the chromocenter as well as the chromosome territory containing the hyperactive X-chromosome in Drosophila. This analysis identified a number of known RNA binding proteins in proximity of the hyperactive X and the centromere, supporting the accuracy of our method. In addition, it enabled us to characterize the role of RNA in the formation of these nuclear bodies. Furthermore, our method identified a new set of RNA molecules associated with the Drosophila centromere. Characterization of these novel molecules suggested the formation of R-loops in centromeres, which we validated using a novel probe for R-loops in Drosophila. Taken together, AMPL-MS improves the selectivity and specificity of proximity ligation allowing for novel discoveries of weak protein-RNA interactions in biologically diverse domains.
-
- Cancer Biology
- Chromosomes and Gene Expression
The chromatin-associated protein WD Repeat Domain 5 (WDR5) is a promising target for cancer drug discovery, with most efforts blocking an arginine-binding cavity on the protein called the ‘WIN’ site that tethers WDR5 to chromatin. WIN site inhibitors (WINi) are active against multiple cancer cell types in vitro, the most notable of which are those derived from MLL-rearranged (MLLr) leukemias. Peptidomimetic WINi were originally proposed to inhibit MLLr cells via dysregulation of genes connected to hematopoietic stem cell expansion. Our discovery and interrogation of small-molecule WINi, however, revealed that they act in MLLr cell lines to suppress ribosome protein gene (RPG) transcription, induce nucleolar stress, and activate p53. Because there is no precedent for an anticancer strategy that specifically targets RPG expression, we took an integrated multi-omics approach to further interrogate the mechanism of action of WINi in human MLLr cancer cells. We show that WINi induce depletion of the stock of ribosomes, accompanied by a broad yet modest translational choke and changes in alternative mRNA splicing that inactivate the p53 antagonist MDM4. We also show that WINi are synergistic with agents including venetoclax and BET-bromodomain inhibitors. Together, these studies reinforce the concept that WINi are a novel type of ribosome-directed anticancer therapy and provide a resource to support their clinical implementation in MLLr leukemias and other malignancies.